Navigation Links
WallSt.net Announces Upcoming Interview With CEO of ReBuilder Medical Technologies
Date:12/17/2007

NEW YORK, Dec. 17 /PRNewswire/ -- David B. Phillips, CEO of ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) (http://www.rebuildermedical.com) will be featured in an exclusive interview with http://www.wallst.net scheduled for December 18th. The interview will be posted on http://www.wallst.net by 8 p.m. EST on December 18th.

The interview will cover topics including ReBuilder Medical Technologies, Inc.'s market potential, growth initiatives, competitive edge, recent news, and milestones for which investors should watch.

To hear the interview in its entirety, visit http://www.wallst.net and click on "Interviews." The interview can be accessed by locating the company's ticker symbol (RBRM) under the appropriate exchange at the top of the "Interviews" section or by entering the company's ticker symbol in the Search Archive window.

About ReBuilder Medical Technologies:

RBRM is a manufacturer of medical devices and innovative technologies founded by world-renowned medical device inventor David B. Phillips, Ph.D. The company's flagship product is its FDA registered ReBuilder System(R), used for treating peripheral neuropathy. Unlike current therapies for neuropathy (nerve disease) that depend on prescription drugs with powerful side effects, the ReBuilder System(R) is a portable, battery-powered medical product that provides a unique, non-surgical treatment which is non-invasive, has no side effects and can actually strengthen muscles while increasing blood flow.

ReBuilder Medical Technologies, Inc. also manufactures the Phillips Molluscum Treatment System(TM) for treating the skin disease Molluscum Contagiosum which primarily affects children. This system uses its proprietary form of micronized amorphous silver ion
'/>"/>

SOURCE Financial Filings Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of Osteologix
2. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
3. WallSt.net Announces Upcoming Interview with CEO of BioSante Pharmaceuticals
4. WallSt.net Announces Upcoming Interview With CEO of Biomoda
5. Synvista Therapeutics to be Featured on Wallst.net
6. WallSt.net Announces Upcoming Interview With CEO Of Immunosyn Corporation
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... DUBLIN , Oct. 22, 2014 ... "Organic Electronics Market by Material, by Application, Geography ... report to their offering. Organic electronics, ... a branch of material science which deals with small ... as organic because small molecules and polymers are carbon ...
(Date:10/20/2014)... 2014 Convey Computer , the ... from Iowa State University won first place in the ... Convey HC-2ex, the team’s solution achieved the highest overall ... the second place finisher. , Experts from all segments ... month long challenge, using a variety of design tools, ...
(Date:10/20/2014)... Oct. 20, 2014  GenVec, Inc. (NASDAQ: GNVC ... , Ph.D., from its board of directors effective on October ... 2003, and served as its chairman from June 2006 to ... Nominating and Corporate Governance and Audit Committees of the board.  ... a decade of dedicated service to GenVec, and its stockholders," ...
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy is ... donor stem cells for dogs with osteoarthritis. Dr. McCarthy ... performed clinical stem cell therapy for 7 years. The ... a single injection of donor stem cells into one ... and inflammation in the treated joints. , Candidates ...
Breaking Biology Technology:Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... (NYSE: DGX ), the world,s leading provider ... for the fourth quarter ended December 31, 2011, adjusted ... per diluted share, compared to $179 million, or $1.03 ... of 2011, reported income from continuing operations was $190 ...
... Lieber, the Mark Hyman Jr. Professor of Chemistry, ... A pioneer in the synthesis of a wide ... unique physical properties of those materials, and the ... Lieber has demonstrated the use of nanoscale materials ...
...  A recent Van Andel Research Institute (VARI) study published in ... function of an essential plant hormone could profoundly change our ... to the development of new drugs for a variety of ... by the same team of investigators at VARI that was ...
Cached Biology Technology:Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 2Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 3Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 4Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 5Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 6Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 7Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 8Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 9Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 10Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 11Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 12Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 13Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 14Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 15Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 16Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 17Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 18Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 19Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 20Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 21Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 22Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 23Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 24Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 25Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 26Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 27Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012 28Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process 2
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
(Date:10/15/2014)... is a non-traditional biophysics textbook and it describes how ... journey of discovery into biological systems and provides an ... It is about how our genes make proteins that ... of cells in an organism. It quantifies the principles ... can be found on both large and small scales. ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2
... help scientists "build" new biological systems, Princeton University scientists ... enable the growth of living cells. The team ... nature, and the scientists showed that they can produce ... as proteins produced by nature,s own toolkit. ...
... ATHENS, Ohio (Jan. 6, 2011) Ohio University ... the bioengineering profession,s highest honor, the Fritz J. and ... Hood of Seattle, Washington, for his discoveries related to ... president and co-founder of the Institute for Systems Biology, ...
... at the University of Connecticut Health Center have identified a ... a predictor of heart attack. Their research, led by ... Cardiology Center, is published in the Jan. 11 issue of ... It found heart attack patients had elevated levels of the ...
Cached Biology News:Princeton scientists construct synthetic proteins that sustain life 2Princeton scientists construct synthetic proteins that sustain life 3DNA sequencing pioneer receives 2011 Russ Prize 2DNA sequencing pioneer receives 2011 Russ Prize 3
Biotin d anti-mouse Tim-1...
Mouse monoclonal [1-N-14] to Adenovirus Type 7 hexon C11 Immunogen: Purified Adenovirus type 7 Specificity: This antibody is specific for Adenovirus type 7 hexon C11....
Request Info...
... is the main excitatory neurotransmitter in the ... considered to act only on the ligand-gated ... that are involved in the fast excitatory ... to regulate enzymes producing second messengers via ...
Biology Products: